Related Experiment Video
Updated: May 29, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Behçet's Syndrome and Thrombosis.
Emire Seyahi1, Sebahattin Yurdakul
1Department of Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.
Behçet syndrome (BS) is a rare vasculitis affecting multiple systems, often presenting with skin lesions and eye inflammation. Vascular complications, particularly venous thrombosis, are common and a major cause of mortality in BS.
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Behçet syndrome (BS) is a multisystem vasculitis of unknown etiology.
- It typically manifests in the third decade with recurrent mucocutaneous lesions and panuveitis.
- Males experience more severe disease than females.
Purpose of the Study:
- To summarize the key features of Behçet syndrome, focusing on its vascular manifestations.
- To highlight the diagnostic hallmarks and common complications of BS.
- To underscore the importance of immunosuppressive treatment.
Main Methods:
- Review of existing literature on Behçet syndrome.
- Analysis of clinical presentation, disease course, and pathological findings.
- Emphasis on vascular involvement patterns and outcomes.
Main Results:
- Vascular involvement occurs in up to 40% of BS cases, affecting all vessel types but favoring veins.
- Common vascular manifestations include lower extremity deep vein thrombosis, vena cava thrombosis, and aneurysms.
- Neutrophilic vasculitis around vaso vasorum is characteristic; thromboembolism is rare despite high venous disease frequency.
Conclusions:
- Behçet syndrome is characterized by significant vascular involvement, a primary driver of mortality.
- Immunosuppressive therapy is crucial for managing BS activity and preventing attacks.
- Further research into BS etiology and pathogenesis is warranted.
Related Concept Videos
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Portal Hypertension
Nephrotic Syndrome I : Introduction
Hemorrhagic Stroke ll: Pathophysiology

